2SEVENTY BIO, INC. - Annual Financials - Equity (SEC)

Updated on January 3, 2026.

Income Statement

Related Topics: SEC Topic List.

Data Source: SEC.

See details in table below.

You can see similar for other companies.

2SEVENTY BIO, INC. - Annual Equity (In Thousands of USD, Except Per Share Amounts)

Breakdown	2024-12-31	2023-12-31	2022-12-31
Beginning balance (in shares)	51589	50632	37928
Beginning balance	779176	-511217	606986
Vesting of restricted stock units (in shares)	867	604
Exercise of stock options (in shares)	6	1
Exercise of stock options	22	7
Issuance of common stock in public offering, net of issuance costs (in shares)		10870
Issuance of common stock in public offering, net of issuance costs		117004
Issuance of common stock to Regeneron (in shares)		1115
Issuance of common stock to Regeneron		9859
Stock-based compensation	12150	32159
Purchase of common stock under ESPP (in shares)	84	114
Purchase of common stock under ESPP	288	702
Other comprehensive income	293	2673
Net loss	-57247	-217570
Ending balance (in shares)	51589	50632	37928
Ending balance	779176	-511217	606986